The Hong Kong IPO prospectus submitted by VivaVision Biotech (Zhejiang) Co., Ltd.-B has lapsed, as the six-month validity period ended on August 13, 2026, for the document filed on February 13, 2026. China International Capital Corporation (CICC) served as the sole sponsor for the listing application.

Founded in 2016, VivaVision is a biotechnology company focused on ophthalmology, aiming to become a global leader in the research, development, and commercialization of innovative eye disease treatments. The company leverages its specialized expertise in small molecule drug discovery for eye diseases, advanced formulation development, and translational medicine research to build a competitive and differentiated product pipeline.

This pipeline targets a range of ophthalmic indications for eye surface and fundus conditions where there are significant unmet clinical needs. VivaVision's two core products are VVN461 (high-dose) and VVN001. VVN461 (high-dose) is a high-dose formulation of VVN461 eye drops, acting as a novel selective dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), with sub-nanomolar potency. The company has initiated a Phase III clinical trial in China for VVN461 (high-dose) in patients with non-infectious anterior uveitis (NIAU).

VVN001 is a second-generation lymphocyte function-associated antigen-1 (LFA-1) antagonist, designed as an innovative eye drop for treating dry eye disease (DED). VivaVision has also commenced a Phase III clinical trial for VVN001 in China. As of the latest practicable date (February 5, 2026), in addition to its core products, the company has six other drug candidates, three of which are in the clinical stage.